Skip to main content
. 2015 May 11;7(4):662–671. doi: 10.1080/19420862.2015.1048411

Table 2.

Key points

• Even fully human monoclonal antibodies are potentially immunogenic
• Antibodies formed in response to treatment are mostly neutralizing
• In many (but not all) cases, pre-existing antibodies have little consequences
• Pre-existing antibodies should be carefully distinguished from false-positive results
• Pre-existing antibodies should be evaluated on a case-by-case basis using assays that yield information on the specificity of the antibodies